AstraZeneca had already promised to supply the European Union with 9 million vaccine doses. BioNTech has agreed to an additional 75 million doses of the coronavirus vaccines, which will be delivered in the coming quarter. There are several reasons for increasing production.
BioNTech plans to expand the delivery of its Covid-19 vaccine to the European Union in the coming quarter. “Up to 75 million more doses will be delivered to the EU in the second quarter,” writes Dr. Sierk Poetting, CFO and COO of BioNTech. “To meet the increased global demand, we plan to produce two billion doses of our Covid-19 vaccine in 2021. To do this, we will increase the previously planned production of 1.3 billion vaccine doses by more than 50 percent. The measures, to expand our production capacities are going according to plan.
According to Poetting, there are several reasons for increasing production. On one hand, the production processes in the Belgian Pfizer plant were completed. “Now we can go back to the original plan for the delivery of vaccine doses to the European Union.” On the other hand, the production facility in Marburg received a manufacturer’s license and could go into operation in February. To this end, BioNTech has expanded the European network from three to 13 partners.
As the EU Commission President Ursula von der Leyen announced on ZDF on Sunday evening, the British-Swedish manufacturer AstraZeneca also wants to deliver more vaccine doses to the EU than recently announced. The company will bring forward its vaccine deliveries to the EU by a week and has promised to increase the number of vaccine doses for the European Union by around nine million units.
According to EU information, AstraZeneca had planned to deliver only 31 million vaccine doses to the EU instead of the originally planned 80 million vaccine doses. According to the new announcement, now the delivery would increase to 40 million doses.